Orion Portfolio Solutions LLC Reduces Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Orion Portfolio Solutions LLC lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) by 29.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,578 shares of the medical equipment provider’s stock after selling 6,775 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Lantheus were worth $1,083,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Parkside Financial Bank & Trust grew its stake in Lantheus by 36.6% during the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 156 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Lantheus by 3.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock worth $432,000 after purchasing an additional 188 shares during the period. Covestor Ltd increased its holdings in shares of Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 203 shares during the period. Renaissance Group LLC raised its position in shares of Lantheus by 1.2% in the third quarter. Renaissance Group LLC now owns 21,350 shares of the medical equipment provider’s stock worth $1,483,000 after buying an additional 262 shares in the last quarter. Finally, Martin Capital Advisors LLP boosted its stake in Lantheus by 2.3% during the fourth quarter. Martin Capital Advisors LLP now owns 11,679 shares of the medical equipment provider’s stock valued at $724,000 after buying an additional 267 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $81.83 on Monday. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The stock has a market cap of $5.67 billion, a PE ratio of 12.49 and a beta of 0.56. The company’s fifty day moving average is $69.37 and its 200 day moving average is $64.57. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $94.47.

Lantheus (NASDAQ:LNTHGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, topping the consensus estimate of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $369.98 million for the quarter, compared to the consensus estimate of $349.46 million. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.51 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total value of $1,454,957.87. Following the transaction, the director now directly owns 23,340 shares in the company, valued at $1,848,294.60. The disclosure for this sale can be found here. Insiders have sold 19,055 shares of company stock valued at $1,502,060 in the last ninety days. Company insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent analyst reports. B. Riley raised their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Mizuho boosted their price target on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Truist Financial upped their target price on shares of Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Finally, JMP Securities reissued a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.17.

Check Out Our Latest Report on LNTH

About Lantheus

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Featured Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.